age disequilibrium analysis showed that the four studied tag SNPs (rs2803073, rs6930532, rs1040079, and rs2276201) were independent. Our results using the multivariate analysis between the additive and dominant model demonstrated that tag SNP rs2803073 of PARK2 is associated with susceptibility to EOC (p = 0.018, OR = 0.42). These findings suggest that hereditary variation in the PARK2 gene could influence EOC development mechanisms.
Introduction
Ovarian cancer (OC) is the eighth most common cancer among women in Brazil [1] and seventh in the world population [2] . OC has a high mortality rate and is difficult to diagnose [3] . It is highly heterogeneous according to cell origin and can be classified into three types: epithelial, stromal, and germ cell. The epithelial form occurs in 90% of all cases [4] . Currently, OC detection most often occurs at an advanced stage of the disease due to its silent progression, which contributes to the high mortality rate [3] .
Studies show an increased risk of development in women with mutations in the BRCA1 (breast cancer 1), BRCA2 (breast cancer 2), PTEN (phosphatase and homolog tensin), and TP53 (protein tumor p53) genes, which are currently used as markers [5] . However, they are not considered specific enough for an initial and definite diagnosis [6] .
PARK2 (parkin RBR E3 ubiquitin protein ligase) [7] encodes the parkin protein that is involved in many cellular processes such as proteasome degradation, xenophagy, cycle control, proliferation and cellular migration, response to oxidative stress, mitochondrial homeostasis, and tumor suppression [8] [9] [10] [11] [12] . Mutations in PARK2 have been associated with juvenile autosomal recessive Parkinsonism [13] , leprosy [14] , diabetes mellitus type 2 [15] , Alzheimer's dementia [16] , multiple sclerosis [17] , attention deficit hyperactivity disorder [18] , autism [19] , typhoid and paratyphoid fever [20, 21] , and more recently to cancer [22] . Among the cancers already presenting PARK2 alterations are: ovarian, breast, kidney, lung, liver, colorectal, melanoma, acute lymphoblastic leukemia, Burkitt's lymphoma, and B-cell nonHodgkin's lymphoma [23] .
The association of new genes involved with OC can provide a better understanding of this pathology, as well as contribute to the development of a marker scenario, providing an improvement in the treatment and survival of patients [24] . The aim of this study was to examine the potential gene association between PARK2 and OC.
Materials and Methods
We obtained peripheral blood samples from 25 white female patients from Erasto Gaertner Hospital, Curitiba, Brazil, diagnosed with epithelial ovarian cancer (EOC) and confirmed by pathological examination. Those under radiotherapy and chemotherapy treatment were excluded. In addition, we included 87 peripheral blood samples of white female controls unrelated to each other from the Hemobanco, Curitiba, Brazil, forming a Southern Brazilian population.
After sample collection, a DNA extraction and purification was carried out by the salting-out technique [25, 26] . Subsequently the samples were diluted, quantified, and stored at -4 ° C until the time of use.
The genotyping of PARK2 was performed using the Applied Biosystems 7500 Real-Time PCR System and the TaqMan TM technology. The amounts and conditions were defined by the manufacturer's specifications. The markers of tag SNP type (rs2803073, rs6930532, rs1040079, and rs2276201) were selected according to the information from the International HapMap Project and in order to allow for a wide coverage of the gene.
The results were analyzed by SPSS 13.0 software, and the differences were considered significant when the p value was <0.05. Based on logistic regression, the ORs of the analyzed alleles were calculated. The degree of linkage disequilibrium (LD) expressed by the parameter r 2 between the four markers was analyzed using the Haploview 4.2 program. The same program was used to verify if the distribution of allele and genotype frequencies were in HardyWeinberg equilibrium.
The tool Firebrowse (http://firebrowse.org/) of the Broad Institute was used for the analysis of The Cancer Genome Atlas (TCGA) ovarian serous cystadenocarcinoma data regarding the PARK2 gene. Moreover, an additional analysis was performed using the available data from the catalogue of somatic mutations in cancer (COSMIC; http://cancer.sanger.ac.uk/cosmic) regarding ovarian carcinoma and PARK2 gene aberrations. 
Results
Allele frequencies observed between the patients and controls are shown in table 1 . This univariate analysis showed no significant difference between EOC and the markers rs1040079 (p = 0.897), rs2276201 (p = 0.732), rs6930532 (p = 0.409), and rs2803073 (p = 0.621). To investigate whether or not the combination of these tag SNPs could influence the development of EOC, and given that it was not possible to explain the susceptibility only by additive and dominant models independently, a multivariate analysis involving the additive and dominant models was performed. This analysis showed a significant association (p = 0.018) between EOC and the marker rs2803073 ( table 2 ) .
LD analysis showed that the markers are independent ( fig. 1 ) , with a low LD between rs1040079 and rs2276201 tag SNPs. All polymorphisms were in Hardy-Weinberg equilibrium.
Taking into consideration the data related to ovarian serous cystadenocarcinoma from the TCGA database, the above-mentioned SNPs have not been described in this type of cancer yet. The same applies to the COSMIC data. This database included only one coding mutation (p.R191R) of the PARK2 gene in 1 out of the 115 studied patients with ovary carcinoma.
Discussion
OC has been associated with somatic changes in several genes, including OPCML [27] , PIK3CA [28] , AKT1 [29] , CTNNB1 [30] , and PARK2 [7] . Germline mutations in the MLH1 gene were associated with susceptibility to familial OC [31] . In the present study, we analyzed changes in germline PARK2 ; therefore, an association with the development of EOC could occur in the hereditary form.
One of the mechanisms of action described for parkin is cell cycle regulation through degradation control of cyclins D and E, which could be related to its role as a tumor suppressor [32] . This protein can also regulate oxidative stress, as well as the Warburg effect, both reported in tumor cells [33] . Alterations in TP53 , commonly described in tumors, may contribute to the downregulation of the expression of PARK2 , resulting in its low transcription [33] .
The LD analysis showed that tag SNPs are independent [34] . Our results using the multivariate analysis between the additive and dominant model demonstrated that tag SNP rs2803073 of PARK2 is associated with susceptibility to EOC (p = 0.018, OR = 0.42). This suggests that a combination of alleles of this gene by unclear mechanisms could result in a genotype of risk for the development of EOC. These findings suggest that hereditary vari- ation in the PARK2 gene could influence cancer development mechanisms. The data from OC patients included in the TCGA and COSMIC databases unfortunately did not include any intronic alterations of the PARK2 gene. As a result, no further correlation with other studied samples could be performed.
Despite the limited PARK2 data in OC patients, one could speculate that in the intronic regions where these SNPs are located, a potential miRNA could be allocated that could upregulate the expression of the PARK2 gene in this type of cancer. This hypothesis can be supported from other studies that suggest that miRNA intronic expression is upregulated in cancer cells [35, 36] .
Considering the correlation with several types of cancer [22] , including OC [37] , our results suggest that PARK2 could also be used as a genetic biomarker for tumor diagnosis, leading to a better understanding of the pathogenesis of EOC.
